Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vaxcyte, Inc. (PCVX)
NASDAQ:PCVX
Holding PCVX?
Track your performance easily
PCVX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$58.10 - $121.06
Previous CloseN/A
Volume105.48K
Average Volume (3M)1.11M
Market Cap
$10.95B
Enterprise Value$11.98B
Total Cash (Recent Filing)$66.09M
Total Debt (Recent Filing)$161.00K
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Mar 03, 2025EPS Estimate
-1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.68
Shares Outstanding124,636,540
10 Day Avg. Volume1,224,033
30 Day Avg. Volume1,109,838
Standard Deviation0.18
R-Squared0.07
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-45.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.09
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-23.87
Forecast
1Y Price Target
$146.57Price Target Upside66.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Vaxcyte News
PremiumCompany Announcements
Vaxcyte, Inc. Navigates AI Risks Amidst Regulatory and Ethical Challenges
PremiumCompany Announcements
Vaxcyte Reports Progress and Strengthens Financial Position
Bulls Say, Bears Say
Bulls Say
Financial HealthVaxcyte has a substantial cash reserve of $3.27B, enabling the company to conduct extensive trials and advance its vaccine programs.
Market PotentialThe VAX-31 asset has become meaningfully derisked, increasing confidence in its regulatory approval and significant commercial potential.
Vaccine DevelopmentVaxcyte's differentiated technology platform has addressed technical limitations in developing more effective next-generation vaccines, positioning the company as a potential leader in the pneumococcal vaccine market.
Bears Say
Competitive ThreatPFE's disclosure of its >30V PCV preclinical development effort is seen as a defensive move against PCVX's competitive threat.
Leadership ChangesThe appointment of RFK Jr as Secretary of HHS initially created concerns about potential changes in vaccine policy that affected the stock.
Market ReactionPfizer's announcement of its >30-valent vaccine led to a sell-off of Vaxcyte's stock.
---
Ownership Overview
0.80% Insiders
46.92% Mutual Funds
0.09% Other Institutional Investors
35.44% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PCVX FAQ
What was Vaxcyte, Inc.’s price range in the past 12 months?
Vaxcyte, Inc. lowest stock price was $58.10 and its highest was $121.06 in the past 12 months.
What is Vaxcyte, Inc.’s market cap?
Vaxcyte, Inc.’s market cap is $10.95B.
When is Vaxcyte, Inc.’s upcoming earnings report date?
Vaxcyte, Inc.’s upcoming earnings report date is Mar 03, 2025 which is in 44 days.
How were Vaxcyte, Inc.’s earnings last quarter?
Vaxcyte, Inc. released its earnings results on Nov 05, 2024. The company reported -$0.83 earnings per share for the quarter, beating the consensus estimate of -$1.101 by $0.271.
Is Vaxcyte, Inc. overvalued?
According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued.
Does Vaxcyte, Inc. pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
What is Vaxcyte, Inc.’s EPS estimate?
Vaxcyte, Inc.’s EPS estimate is -1.1.
How many shares outstanding does Vaxcyte, Inc. have?
Vaxcyte, Inc. has 124,636,540 shares outstanding.
What happened to Vaxcyte, Inc.’s price movement after its last earnings report?
Vaxcyte, Inc. reported an EPS of -$0.83 in its last earnings report, beating expectations of -$1.101. Following the earnings report the stock price went down -3.245%.
Which hedge fund is a major shareholder of Vaxcyte, Inc.?
Among the largest hedge funds holding Vaxcyte, Inc.’s share is RA Capital Management. It holds Vaxcyte, Inc.’s shares valued at 993M.
---
Vaxcyte Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$146.57 (66.88% Upside)
$146.57 (66.88% Upside)
Blogger Sentiment
Bullish
PCVX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 10.8%
Last 30 Days ▲ 10.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
42.23%
12-Months-Change
Fundamentals
Return on Equity
-21.06%
Trailing 12-Months
Asset Growth
137.94%
Trailing 12-Months
Company Description
Vaxcyte, Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from most common and deadly diseases.
---
PCVX Company Deck
---
PCVX Earnings Call
Q4 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in financial strength, clinical development, and regulatory interactions, particularly with VAX-24 and VAX-31. However, there are challenges related to achieving desired serotype coverage and uncertainties in Phase III progress and FDA approval. Overall, the company is well-positioned but faces some strategic decisions and regulatory hurdles.Read More>---
PCVX Stock 12 Month Forecast
Average Price Target
$146.57
▲(66.88% Upside)
Technical Analysis
Moderna
―
Novavax
―
Inovio Pharmaceuticals
―
Ionis Pharmaceuticals
―
Alnylam Pharma
―
Arcturus Therapeutics
―
Best Analysts Covering PCVX
1 Year
1 Year Success Rate
20/23 ratings generated profit
1 Year Average Return
+44.81%
reiterated a buy rating 2 months ago
Copying Joseph Stringer's trades and holding each position for 1 Year would result in 86.96% of your transactions generating a profit, with an average return of +44.81% per trade.
---